Search research articles
Contact Us
Filters
Showing results (11-20 of 29) with videos related to
Page
of 3
Sort By:
Reproductive Sciences (Thousand Oaks, Calif.)
|
September 25, 2015
Effects of the Oral Oxytocin Receptor Antagonist Tocolytic OBE001 on Reproduction in Rats
Oliver Pohl, Deborah Perks, Jon Rhodes, et al.
Plos Computational Biology
|
January 24, 2017
Inferring the Chemotactic Strategy of P. putida and E. coli Using Modified Kramers-Moyal Coefficients
Oliver Pohl, Marius Hintsche, Zahra Alirezaeizanjani, et al.
British Journal of Clinical Pharmacology
|
March 21, 2019
Coadministration of the prostaglandin F2α receptor antagonist preterm labour drug candidate OBE022 with magnesium sulfate, atosiban, nifedipine and betamethasone
Oliver Pohl, Line Marchand, Jean-Pierre Gotteland, et al.
British Journal of Clinical Pharmacology
|
December 14, 2021
A model-based analysis to guide gonadotropin-releasing hormone receptor antagonist use for management of endometriosis
Oliver Pohl, Kyle Baron, Matthew Riggs, et al.
Current Drug Safety
|
May 10, 2013
Carcinogenicity and chronic rodent toxicity of the selective progesterone receptor modulator ulipristal acetate
Oliver Pohl, Philip W Harvey, Sean McKeag, et al.
British Journal of Clinical Pharmacology
|
May 1, 2018
Pharmacokinetics, safety and tolerability of OBE022, a selective prostaglandin F2α receptor antagonist tocolytic: A first-in-human trial in healthy postmenopausal women
Oliver Pohl, Line Marchand, Jean-Pierre Gotteland, et al.
Clinical and Translational Science
|
June 27, 2026
PBPK Modeling and Clinical Data Reveal Reduced Impact of CYP3A4 and CYP2C9 Inhibitors on Elimination of Siponimod
Felix Huth, Kasra Shakeri-Nejad, Anne Gardin, et al.
Reproductive Biomedicine Online
|
June 25, 2021
The mechanism of action of oxytocin antagonist nolasiban in ART in healthy female volunteers
Piotr Pierzyński, Oliver Pohl, Line Marchand, et al.
Clinical Pharmacology in Drug Development
|
March 1, 2018
Confirmation of the Cardiac Safety of PGF<sub>2α</sub> Receptor Antagonist OBE022 in a First-in-Human Study in Healthy Subjects, Using Intensive ECG Assessments
Jörg Täubel, Ulrike Lorch, Simon Coates, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 3, 2014
Social interactions dominate speed control in poising natural flocks near criticality
William Bialek, Andrea Cavagna, Irene Giardina, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 29) with videos related to
Sort By:
Page
of 3
Reproductive Sciences (Thousand Oaks, Calif.)
|
September 25, 2015
Effects of the Oral Oxytocin Receptor Antagonist Tocolytic OBE001 on Reproduction in Rats
Oliver Pohl, Deborah Perks, Jon Rhodes, et al.
Plos Computational Biology
|
January 24, 2017
Inferring the Chemotactic Strategy of P. putida and E. coli Using Modified Kramers-Moyal Coefficients
Oliver Pohl, Marius Hintsche, Zahra Alirezaeizanjani, et al.
British Journal of Clinical Pharmacology
|
March 21, 2019
Coadministration of the prostaglandin F2α receptor antagonist preterm labour drug candidate OBE022 with magnesium sulfate, atosiban, nifedipine and betamethasone
Oliver Pohl, Line Marchand, Jean-Pierre Gotteland, et al.
British Journal of Clinical Pharmacology
|
December 14, 2021
A model-based analysis to guide gonadotropin-releasing hormone receptor antagonist use for management of endometriosis
Oliver Pohl, Kyle Baron, Matthew Riggs, et al.
Current Drug Safety
|
May 10, 2013
Carcinogenicity and chronic rodent toxicity of the selective progesterone receptor modulator ulipristal acetate
Oliver Pohl, Philip W Harvey, Sean McKeag, et al.
British Journal of Clinical Pharmacology
|
May 1, 2018
Pharmacokinetics, safety and tolerability of OBE022, a selective prostaglandin F2α receptor antagonist tocolytic: A first-in-human trial in healthy postmenopausal women
Oliver Pohl, Line Marchand, Jean-Pierre Gotteland, et al.
Clinical and Translational Science
|
June 27, 2026
PBPK Modeling and Clinical Data Reveal Reduced Impact of CYP3A4 and CYP2C9 Inhibitors on Elimination of Siponimod
Felix Huth, Kasra Shakeri-Nejad, Anne Gardin, et al.
Reproductive Biomedicine Online
|
June 25, 2021
The mechanism of action of oxytocin antagonist nolasiban in ART in healthy female volunteers
Piotr Pierzyński, Oliver Pohl, Line Marchand, et al.
Clinical Pharmacology in Drug Development
|
March 1, 2018
Confirmation of the Cardiac Safety of PGF<sub>2α</sub> Receptor Antagonist OBE022 in a First-in-Human Study in Healthy Subjects, Using Intensive ECG Assessments
Jörg Täubel, Ulrike Lorch, Simon Coates, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 3, 2014
Social interactions dominate speed control in poising natural flocks near criticality
William Bialek, Andrea Cavagna, Irene Giardina, et al.
Page
of 3